Trial Profile
Clinical effects of everolimus in the subjects with tuberous sclerosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Sep 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Tuberous sclerosis
- Focus Therapeutic Use
- 18 Sep 2022 Planned number of patients changed from 45 to 20.
- 27 Sep 2021 Planned End Date changed to 10 Apr 2026.
- 27 Sep 2021 Timepoint of primary endpoint has been changed from September, 2023 to September, 2026